A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation

A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation

Hantaan virus (HTNV) and Puumala virus (PUUV) are pathogenic hantaviruses found in Asia and Europe, respectively. DNA vaccines targeting the envelope glycoproteins of these viruses have been constructed and found to elicit neutralizing antibodies when delivered to humans by various technologies incl...

Full description

Bibliographic Details
Main Authors: Jay Hooper, K. M. Paolino, K. Mills, S. Kwilas, M. Josleyn, M. Cohen, B. Somerville, M. Wisniewski, S. Norris, B. Hill, M. Sanchez-Lockhart, D. Hannaman, C. S. Schmaljohn
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Vaccines
Subjects:
hantavirus
hemorrhagic fever with renal syndrome
DNA vaccine
electroporation
Online Access:https://www.mdpi.com/2076-393X/8/3/377

Internet

https://www.mdpi.com/2076-393X/8/3/377

Similar Items